scholarly article | Q13442814 |
case report | Q2782326 |
P50 | author | Evangelos N Liberopoulos | Q37830431 |
Eleni Papadokostaki | Q64904771 | ||
P2860 | cites work | Hyperglycemic crises in adult patients with diabetes | Q22241293 |
SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 | ||
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus | Q30426632 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program | Q35973246 | ||
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System | Q36370828 | ||
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
SGLT inhibitors in management of diabetes | Q38195440 | ||
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. | Q38778239 | ||
Euglycemic Diabetic Ketoacidosis | Q38812956 | ||
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis | Q39047440 | ||
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial | Q47770648 | ||
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. | Q50716118 | ||
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. | Q50955035 | ||
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 | ||
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Q57026285 | ||
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials | Q57026286 | ||
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study | Q59330606 | ||
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials | Q61458485 | ||
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Q63071417 | ||
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS | Q63071443 | ||
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial | Q64129222 | ||
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors | Q64385669 | ||
Euglycaemic diabetic ketoacidosis | Q67246133 | ||
Relationship between severity of hyperglycemia and metabolic acidosis in diabetic ketoacidosis | Q70411990 | ||
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study | Q90826991 | ||
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits | Q91071787 | ||
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes | Q92980564 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | diabetic ketoacidosis | Q877827 |
P304 | page(s) | 3901741 | |
P577 | publication date | 2019-05-06 | |
P1433 | published in | Case reports in endocrinology | Q27724372 |
P1476 | title | Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. | |
P478 | volume | 2019 |
Search more.